List of Excipients in Branded Drug TABRECTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	TABRECTA	capmatinib	0078-0709	CELLULOSE, MICROCRYSTALLINE	2035-07-22
Novartis Pharmaceuticals Corporation	TABRECTA	capmatinib	0078-0709	CROSPOVIDONE	2035-07-22
Novartis Pharmaceuticals Corporation	TABRECTA	capmatinib	0078-0709	FERRIC OXIDE RED	2035-07-22
Novartis Pharmaceuticals Corporation	TABRECTA	capmatinib	0078-0709	FERRIC OXIDE YELLOW	2035-07-22
Novartis Pharmaceuticals Corporation	TABRECTA	capmatinib	0078-0709	FERROSOFERRIC OXIDE	2035-07-22
Novartis Pharmaceuticals Corporation	TABRECTA	capmatinib	0078-0709	HYPROMELLOSES	2035-07-22
Novartis Pharmaceuticals Corporation	TABRECTA	capmatinib	0078-0709	MAGNESIUM STEARATE	2035-07-22

# TABRECTA Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Tabrecta (capmatinib) is an oral small-molecule MET inhibitor approved by the FDA for adults with metastatic non-small cell lung cancer whose tumors harbor mutations leading to MET exon 14 skipping. Its commercial opportunity is concentrated in biomarker-selected oncology, where differentiation is driven by diagnostic access, tolerability, convenient oral dosing, and lifecycle management rather than by excipient novelty alone. The current tablet platform uses conventional excipients, leaving potential opportunities in alternate dosage forms, adherence-oriented packaging, manufacturing efficiency, and generic substitution strategies. [1]

What excipients are used in TABRECTA tablets?

Tabrecta is supplied as immediate-release film-coated tablets in 150 mg and 200 mg strengths. The FDA prescribing information identifies the following inactive ingredients:

Excipient	Likely formulation role
Colloidal silicon dioxide	Glidant and flow aid
Crospovidone	Superdisintegrant
Hypromellose	Film-forming polymer
Magnesium stearate	Lubricant
Microcrystalline cellulose	Diluent and compression aid
Povidone	Binder
Sodium lauryl sulfate	Wetting agent and dissolution aid
Talc	Coating aid and anti-tacking agent
Titanium dioxide	Opacifier and whitening agent
Yellow iron oxide	Tablet colorant
Red iron oxide	Colorant used in the 150 mg strength

The core formulation relies on standard direct-compression or dry-granulation excipient technology. It does not depend on a novel lipid system, amorphous solid dispersion, modified-release polymer, or device-based delivery platform. [1]

What does the excipient profile indicate about manufacturing?

The formulation has a relatively low technical barrier to manufacture. Microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, sodium lauryl sulfate, and magnesium stearate are widely available from multiple global suppliers. The film coat uses common pharmaceutical coating materials.

The main manufacturing controls are likely to involve:

• Blend uniformity at a relatively low drug-load ratio.
• Lubrication control to prevent dissolution delay.
• Wetting and disintegration performance.
• Color matching between tablet strengths.
• Film-coat adhesion, defect control, and moisture management.
• Control of capmatinib particle size and solid-state properties.

Because the excipients are conventional, supplier substitution is commercially feasible if the finished product maintains dissolution, assay, impurities, stability, and bioequivalence specifications.

How does capmatinib’s biopharmaceutic profile affect excipient strategy?

Capmatinib can be administered with or without food. The FDA label reports increased exposure when administered with food, including a 46% increase in area under the curve with a high-fat meal and a 20% increase with a low-fat meal. The approved label nevertheless permits dosing with or without food, which simplifies patient instructions and reduces the need for meal-linked packaging. [1]

This profile creates several formulation priorities:

1. Preserve consistent dissolution across physiologically relevant pH conditions.
2. Avoid excessive dependence on sodium lauryl sulfate or other surfactants that could create tolerability or manufacturing concerns.
3. Maintain tablet robustness without excessive magnesium stearate lubrication.
4. Support reliable exposure despite variable patient meal patterns.
5. Minimize tablet burden for patients receiving combination regimens.

A reformulation that materially changes food sensitivity could create regulatory and commercial disadvantages, even if it improves laboratory dissolution. The current with-or-without-food label is a useful product attribute.

What formulation opportunities exist for TABRECTA?

The most credible opportunities are incremental rather than transformational.

Lower-dose and dose-flexibility products

The approved strengths are 150 mg and 200 mg, with the recommended adult dosage generally administered twice daily. The two strengths permit dose adjustment, but a lower-strength tablet could improve titration for patients experiencing adverse reactions or organ-function-related dose modifications.

A 50 mg or 100 mg strength could support:

• More precise dose reductions.
• Reduced tablet splitting or complex combinations of strengths.
• Better management of renal or hepatic impairment.
• Easier clinical trial dose-ranging.
• Improved adherence during toxicity management.

Any new strength would require pharmaceutical development, stability data, dissolution comparability, and an FDA supplement. The commercial value would depend on the frequency of dose reductions and payer willingness to reimburse an additional SKU.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with dysphagia, advanced thoracic disease, poor oral intake, or difficulty swallowing multiple tablets. The opportunity is technically plausible but not automatically attractive. Capmatinib’s dose, taste, moisture sensitivity, and required twice-daily administration would influence feasibility.

Potential excipient systems could include:

• Mannitol-based orally disintegrating matrices.
• Crospovidone or sodium starch glycolate as disintegrants.
• Flavors and sweeteners for palatability.
• Low-moisture blister packaging.
• Taste-masking polymers or coated drug particles.

The principal risk is that a fast-disintegrating product may alter absorption or food sensitivity. A clinical bridging strategy would be needed if the new dosage form changes pharmacokinetic exposure.

Sprinkle or dispersed-tablet presentations

A dispersible or sprinkle formulation could serve patients who cannot swallow conventional tablets. The product would need clear instructions on dispersion medium, administration time, tube compatibility, and stability after dispersion.

Commercial value is strongest in supportive-care settings and selected oncology populations. Pediatric use would require separate regulatory work because Tabrecta is not established as a pediatric product under the current label. [1]

Modified-release formulations

A once-daily modified-release capmatinib product could reduce dosing frequency, but it is likely a lower-priority opportunity. The existing twice-daily regimen may reflect pharmacokinetic and exposure requirements. A controlled-release product would need to demonstrate adequate exposure, food-effect control, dose proportionality, and noninferiority or superiority in adherence-related outcomes.

Modified release could support a new patent position, but the development cost and clinical burden would be significantly higher than for a conventional strength extension.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers have several entry points despite the mature formulation.

Functional excipient supply

Commercial opportunities include qualified supply of:

• High-functionality microcrystalline cellulose.
• Consistent-grade crospovidone.
• Low-peroxide povidone.
• Controlled-particle-size colloidal silicon dioxide.
• Pharmaceutical-grade sodium lauryl sulfate.
• Film-coating systems with reproducible color performance.

The most defensible supplier position would come from validated performance rather than commodity pricing. A supplier offering reduced variability in blend flow, tablet hardness, disintegration, or coating uniformity could create switching costs during technology transfer.

Color and coating optimization

The two tablet strengths use different color profiles. A standardized premix coating system could reduce batch-to-batch color variation and simplify manufacturing across sites. This is a practical opportunity for film-coating suppliers, particularly where manufacturers seek lower solvent use, faster coating cycles, or improved defect rates.

Continuous manufacturing

Tabrecta’s conventional excipient system is compatible with continuous manufacturing concepts. Continuous blending and tablet compression could reduce material hold times, improve process monitoring, and lower waste. The commercial opportunity lies in integrated process analytical technology, not in a proprietary excipient alone.

Excipient substitution for global supply resilience

A second-source strategy could address regional shortages, freight constraints, or geopolitical risk. The most likely candidates for qualification are microcrystalline cellulose, crospovidone, povidone, magnesium stearate, and coating components. Substitution must preserve critical quality attributes and may require regulatory documentation, depending on the change and jurisdiction.

What is the FDA regulatory status of TABRECTA?

The FDA approved Tabrecta on May 6, 2020, under the accelerated approval pathway for metastatic NSCLC with MET exon 14 skipping alterations. The approval was based on overall response rate and duration of response in the GEOMETRY mono-1 trial. The drug was approved with the FoundationOne CDx as a companion diagnostic for identifying eligible patients. [2]

Regulatory item	Status
Active ingredient	Capmatinib
Brand	Tabrecta
Sponsor	Novartis Pharmaceuticals Corporation
Dosage form	Immediate-release film-coated tablet
Strengths	150 mg and 200 mg
Initial FDA approval	May 6, 2020
Target population	Adults with metastatic NSCLC with MET exon 14 skipping alterations
Diagnostic pathway	FDA-approved companion diagnostic testing
Biologic product	No
Generic pathway	ANDA under Hatch-Waxman
Biosimilar pathway	Not applicable

The diagnostic requirement materially narrows the addressable population but improves treatment selection. Commercial expansion depends on testing rates, tissue availability, use of liquid biopsy, and oncologist adoption of MET testing at diagnosis and progression.

When does TABRECTA lose exclusivity?

Tabrecta is a small-molecule drug, so generic competition would proceed through an ANDA rather than a biosimilar application. A generic applicant could challenge listed patents through a Paragraph IV certification, seek a non-infringement or invalidity position, or wait for relevant patent expiry.

The commercial exclusivity analysis should separate four categories:

1. FDA regulatory exclusivity.
2. Orange Book-listed drug-substance or drug-product patents.
3. Method-of-use patents covering MET exon 14 skipping NSCLC.
4. Non-Orange Book rights, including manufacturing, crystalline form, process, or international patents.

The Orange Book is the controlling source for U.S. listed patents and regulatory exclusivity status. [3] Formulation-related rights may be narrower than compound patents and may be vulnerable if a generic can use a different excipient system while meeting bioequivalence requirements.

What generic entry risks exist for Tabrecta?

The principal generic entry risks are:

• A Paragraph IV challenge to a composition-of-matter patent.
• A validity challenge based on obviousness, written description, or enablement.
• Design-around of formulation claims using different disintegrants, binders, lubricants, or coating systems.
• A non-infringing generic tablet that matches dissolution and exposure without copying the excipient percentages.
• A settlement allowing a launch before the latest asserted patent expiry.

The conventional excipient profile increases design-around feasibility. A generic manufacturer would not need to reproduce the exact excipient list unless a particular formulation claim required it.

What formulation patents could protect capmatinib products?

Formulation patent value would depend on claim scope. Potential claim categories include:

• Specific capmatinib polymorphs or crystalline forms.
• Particle-size distributions.
• Tablet compositions defined by excipient ranges.
• Dissolution profiles.
• Film-coat compositions.
• Stability improvements.
• Reduced food-effect formulations.
• Alternate dosage forms.
• Manufacturing processes that produce a defined solid-state form.

A broad composition-of-matter patent generally provides stronger protection than a narrow tablet claim. A formulation patent covering a precise excipient ratio may be easier to design around, particularly where the excipients are pharmaceutically conventional.

Method-of-use patents could cover treatment of MET exon 14 skipping NSCLC, dosing schedules, patient-selection criteria, or combinations with other anticancer agents. Enforcement against an ANDA applicant can be more complex where the generic label omits or carves out a patented use.

How strong is the TABRECTA patent estate?

The estate’s practical strength depends on the surviving scope and duration of compound, formulation, method-of-use, and process claims. The underlying capmatinib molecule and MET-targeted use claims are likely to carry greater strategic value than conventional excipient claims.

A strong commercial estate would normally have:

• A composition-of-matter patent with meaningful remaining term.
• Multiple continuation or divisional applications.
• Separate protection for polymorphs and solid-state forms.
• Method-of-use claims aligned with the FDA label.
• International coverage in major oncology markets.
• Patent claims that are difficult to avoid through excipient substitution.

A weaker estate would rely mainly on narrow formulation claims or late-filed method-of-use claims. Generic applicants could then pursue a tablet design using alternative binders, disintegrants, lubricants, or coating materials.

Which companies are positioned to challenge TABRECTA?

Potential generic challengers would include established ANDA manufacturers with oncology portfolios and experience developing high-value oral small molecules. The most credible competitors would be companies with:

• FDA-approved oncology tablets.
• Internal bioequivalence and dissolution laboratories.
• Paragraph IV litigation experience.
• Manufacturing capacity for controlled substances or high-potency oncology compounds, where applicable.
• Access to MET diagnostic and commercial distribution channels.

No biosimilar company is relevant because capmatinib is a chemically synthesized small molecule rather than a biologic.

How does TABRECTA compare with competing MET inhibitors?

Product	Active ingredient	MET positioning	Dosage form	Excipient opportunity
Tabrecta	Capmatinib	MET exon 14 skipping NSCLC	Immediate-release tablet	Strength extension, ODT, dispersible product, supplier substitution
Tepmetko	Tepotinib	MET exon 14 skipping NSCLC	Tablet	Differentiation through dosing, tolerability, and formulation convenience
Xalkori	Crizotinib	ALK, ROS1, and MET-related uses	Capsule	Older product with broader historical biomarker positioning

Tabrecta competes most directly with Tepmetko in MET exon 14 skipping NSCLC. Excipient innovation alone is unlikely to change the competitive ranking. The larger commercial variables are diagnostic penetration, treatment sequencing, adverse-event management, payer coverage, and evidence in real-world patient populations.

What licensing and partnership opportunities exist?

The most plausible licensing opportunities are adjacent to the finished product:

• Companion-diagnostic distribution and testing partnerships.
• Regional commercialization rights.
• Alternate dosage-form technology licenses.
• Contract manufacturing and packaging agreements.
• Excipient supplier development agreements.
• Digital adherence and specialty-pharmacy support.
• Combination-therapy development with immunotherapy or other targeted agents.

A licensing deal based solely on the existing excipient composition would have limited value because the ingredients are widely available. A stronger transaction would combine capmatinib rights with a differentiated dosage form, a validated manufacturing process, or a diagnostic platform that expands MET testing.

What is the outlook for Tabrecta commercial exposure?

Tabrecta’s revenue exposure is tied to a defined molecular subgroup of metastatic NSCLC rather than the entire lung-cancer market. The commercial ceiling is therefore sensitive to:

• Incidence of MET exon 14 skipping alterations.
• Routine use of broad next-generation sequencing panels.
• Reimbursement for companion-diagnostic testing.
• Competition from Tepmetko and later MET-directed therapies.
• Duration of treatment before progression or intolerance.
• Generic timing after patent challenges.
• Uptake in community oncology practices.

The strongest near-term formulation opportunity is a lower-strength or patient-friendly oral presentation. The strongest supply-chain opportunity is multi-source qualification of critical excipients and coating systems. The strongest intellectual-property opportunity is a differentiated solid form, reduced food-effect formulation, or alternate dosage form with clinically meaningful advantages.

Key Takeaways

• Tabrecta uses a conventional immediate-release film-coated tablet platform with widely available excipients.
• The identified excipients include microcrystalline cellulose, crospovidone, povidone, sodium lauryl sulfate, magnesium stearate, hypromellose, talc, titanium dioxide, iron oxides, and colloidal silicon dioxide.
• The most credible product opportunities are a lower-strength tablet, orally disintegrating tablet, dispersible formulation, or improved packaging system.
• Conventional excipients make generic design-around relatively feasible.
• Capmatinib is subject to Hatch-Waxman generic competition, not biosimilar competition.
• Patent value is likely to be concentrated in compound, solid-state, method-of-use, and clinically differentiated formulation claims.
• Commercial growth depends heavily on MET exon 14 testing, companion-diagnostic access, treatment sequencing, and competition with tepotinib.
• Excipient suppliers have opportunities in validated second sourcing, functional excipient performance, coating systems, and continuous manufacturing.

FAQs

Can Tabrecta tablets be reformulated without conducting a new clinical trial?

Some excipient or manufacturing changes may qualify for a regulatory supplement supported by pharmaceutical equivalence, dissolution, stability, and other comparability data. A new clinical study may be required if the change materially affects exposure, food effect, safety, or bioavailability.

Is lactose present in the approved Tabrecta formulation?

The FDA prescribing information lists the inactive ingredients without lactose among the identified excipients. The commercial product label should control for any market-specific formulation change. [1]

Could a generic Tabrecta use different excipients?

Yes. An ANDA applicant generally must demonstrate pharmaceutical equivalence and bioequivalence, but it does not ordinarily need to copy every inactive ingredient or quantitative excipient level unless required by a specific patent claim or regulatory condition.

Would an orally disintegrating Tabrecta tablet create new patent value?

It could. Patentability would depend on the formulation’s composition, dissolution behavior, stability, taste masking, pharmacokinetic profile, and non-obviousness. A clinically useful reduction in swallowing burden or food sensitivity would strengthen the commercial rationale.

Does Tabrecta have biosimilar risk?

No. Capmatinib is a synthetic small-molecule drug. Competitive entry would occur through generic-drug applications, including possible Paragraph IV patent challenges.

References

1. U.S. Food and Drug Administration. (2024). Tabrecta (capmatinib) tablets: Prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (2020, May 6). FDA approves capmatinib for metastatic non-small cell lung cancer. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm